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Background: A translational study in renal transplantation suggested YKL-40, a chitinase 3-like-1 gene product,
plays an important role in acute kidney injury (AKI) and repair, but data are lacking about this protein in urine from
native human kidneys.
Methods: This is an ancillary study to a single-center, prospective observational cohort of patients with
clinically-defined AKI according to AKI Network serum creatinine criteria. We determined the association of
YKL −40 ≥ 5 ng/ml, alone or combined with neutrophil gelatinase-associated lipocalin (NGAL), in urine collected
on the first day of AKI with a clinically important composite outcome (progression to higher AKI stage and/or
in-hospital death).
Results: YKL-40 was detectable in all 249 patients, but urinary concentrations were considerably lower than in
previously measured deceased-donor kidney transplant recipients. Seventy-two patients (29%) progressed or died
in-hospital, and YKL-40 ≥ 5 ng/ml had an adjusted odds ratio (95% confidence interval) for the outcome of 3.4
(1.5-7.7). The addition of YKL-40 to a clinical model for predicting the outcome resulted in a continuous net
reclassification improvement of 29% (P = 0.04). In patients at high risk for the outcome based on NGAL concentrations
in the upper quartile, YKL-40 further partitioned the cohort into moderate-risk and very high-risk groups.
Conclusions: Urine YKL-40 is associated with AKI progression and/or death in hospitalized patients and improves
clinically determined risk reclassification. Combining YKL-40 with other AKI biomarkers like NGAL may further delineate
progression risk, though additional studies are needed to determine whether YKL-40 has general applicability and to
define its association with longer-term outcomes in AKI.
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Acute kidney injury (AKI) is common and appears to be
increasing among hospitalized patients [1-3]. Observa-
tional studies demonstrate that even transient AKI is
associated with adverse events ranging from increased
hospital length of stay, to the development of end-stage
renal disease and death [4-6]. However, the biological
mechanisms that underlie the relationship between
episodes of transient AKI and outcomes are not well
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unless otherwise stated.In patients traditionally categorized as having “pre-renal”
AKI, temporary increases in serum creatinine (SCr) con-
centrations are caused by changes in fluid status and/or
renal perfusion. When there is no structural kidney dam-
age in these cases, the diagnosis of AKI may not be causally
associated with adverse outcomes. Conversely, a subgroup
of patients within the current AKI classification scheme
have structural kidney injury and are likely to be at higher
risk of significant outcomes directly attributable to their
renal diagnosis. Inability to discriminate such a group may
have contributed to the lack of success in developing treat-
ments for AKI [7].
We have evaluated the potential diagnostic and prog-
nostic roles of several protein biomarkers measured
from blood and urine in different clinical AKI settings
[8-11]. One of the most promising biomarkers from our. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lipocalin (NGAL), a 25 kDa protein expressed at low levels
by several cell types but at particularly high levels by cells
in the distal nephron during periods of structural kidney
injury [12]. While actively examining biomarkers like
NGAL, we have also continued to investigate the potential
clinical utility for other proteins not previously described
in the context of AKI. As such, our group recently showed
that the products of the chitinase 3-like-1 gene (called
BRP-39 in the mouse and YKL-40 in man) modulate renal
repair mechanisms after ischemic kidney injury in mice
and can act as effective markers of renal injury in the set-
ting of kidney transplantation in man [13]. By this model,
YKL-40 levels should be low in pre-renal AKI but relatively
high when overt structural kidney injury triggers repair
mechanisms and contributes to clinical outcomes.
Pepe and colleagues described 5 phases of biomarker
development for detecting cancer [14]; however, the
same categories can be applied to biomarker studies of
kidney injury and repair. Accordingly, in this phase 3
biomarker development and proof-of-concept study, we
investigated whether urine YKL-40 on the day of AKI
diagnosis from any cause can help predict outcome in
hospitalized patients. In mouse models, BRP-39 does not
rise until 24 hours after a renal insult and peaks on day 3.
The delay from renal insult to clinical AKI diagnosis by
SCr criteria is typically more than 24 hours, so we postu-
lated that YKL-40 levels could already be discriminatory
in urine collected on the day of AKI diagnosis. We also
hypothesized that further prognostic information would
be provided by a model that incorporates urine levels of
both YKL-40 and NGAL, the most predictive AKI bio-
marker previously measured in this mixed cohort of hos-
pitalized patients.
Methods
This is an ancillary study to the previously described
hospitalized AKI cohort [8]. Briefly, we prospectively
screened all patients aged at least 18 years at Yale-New
Haven Hospital between 2008 and 2009 for AKI Network
SCr criteria (urine output not used) [15]. Patients were
eligible if admitted with at least stage 1 AKI (using
outpatient SCr as baseline) or developed at least stage 1
AKI during the hospitalization. We excluded patients with
end-stage kidney disease or kidney transplant, those dis-
charged within 24 hours of enrollment, and those with
stage 3 AKI at enrollment (as we wanted to detect progres-
sion from mild/moderate AKI to more severe outcomes).
AKI stage on the day of diagnosis and peak AKI stage
during the admission were determined relative to base-
line SCr: stage 1, increase in SCr by ≥0.3 mg/dl or 0.5
to <2-fold increase; stage 2, 2 to <3-fold increase; and
stage 3, ≥3-fold increase, or SCr ≥4.0 mg/dl after a rise of
at least 0.5 mg/dl, or acute dialysis requirement.Baseline glomerular filtration rate (GFR) was esti-
mated from baseline SCr using the 4-variable Modifi-
cation of Diet in Renal Disease study equation [16].
Other patient characteristics (including comorbidities)
were recorded from the medical histories obtained by
admitting/consulting physicians. For descriptive pur-
poses, AKI type was determined by retrospective chart
adjudication as previously described [8]. Study physi-
cians considered all available notes and hospital data
(e.g., nephrology consult notes and urine electrolytes when
available, changes in creatinine and urine output, timing
and amount of fluids given, patient disposition, etc.) to
classify AKI as acute tubular necrosis (ATN), pre-renal
azotemia, or “other”. The primary outcome was a compos-
ite of worsened AKI Network stage or in-hospital death.
For further details, see our previous publication from this
cohort.
We adhered to the Declaration of Helsinki in conducting
this study, which was approved by the Yale Institutional
Review Board (IRB). Waiver of written consent allowed for
the immediate collection of urine (that would have other-
wise been discarded) in real time from any patient that met
inclusion criteria along with their de-identified hospital in-
formation and pre-admission baseline SCr.
Specimen handling and biomarker measurement
One 10-ml urine sample was collected from the catheter
tubing, or a clean catch was requested directly from
the patient within a few hours of the routine morning
blood draw that indicated the patient had AKI. Samples
were immediately refrigerated and then centrifuged at
5000 × g for 10 minutes at 4°C within 4 hours of collection.
Samples were stored in separated, 1 mL aliquots without
additives at −80°C till biomarker measurements. Urine
YKL-40 levels were assessed in the last quarter of 2012
using enzyme-linked immunosorbent assay (ELISA) kits
as previously described (Quidel, San Diego, CA) [13].
Population based urine levels have not been defined for
YKL-40, but published data for 22 non-diabetic patients
with normal renal function indicate urine YKL-40 is typ-
ically undetectable or less than 0.2 ng/ml in healthy indi-
viduals [17]. Urine NGAL levels were measured via
ELISA by the Devarajan laboratory between 2008 and
2009 as reported in our prior publication [8]. Population
mean levels of urine NGAL in healthy adults are between
10–23 ng/ml [18]. Note, the documented intra-assay and
inter-assay coefficients of variation for both YKL-40 and
NGAL ELISA methods are less than 10%. All laboratory
measurements were performed by personnel blinded to
patient information.
Statistical analysis
Our previously described baseline clinical model for
predicting risk of the primary outcome included the











Age ≥65 years 143 (57) 121 (56) 22 (71) 0.10
Male sex 143 (57) 125 (57) 18 (58) 0.94
Non-White race 59 (24) 52 (24) 7 (23) 0.88
Body Mass Index, kg/m2 29.9 ± 8 30 ± 8 27 ± 6 0.06
Clinical Characteristics
Pre-existing CKD 62 (25) 54 (25) 8 (27) 0.87
Pre-existing proteinuria 63 (32) 49 (29) 14 (50) 0.03
ACEi/ARB at enrollment 88 (36) 78 (37) 10 (34) 0.82
Hypertension 171 (69) 147 (68) 24 (77) 0.28
Diabetes 102 (41) 88 (41) 14 (45) 0.64
CHF 92 (37) 83 (39) 9 (29) 0.30
CAD 102 (41) 88 (41) 14 (47) 0.52
Stroke 34 (14) 26 (12) 8 (26) 0.04
Liver failure/Cirrhosis 27 (11) 24 (11) 3 (10) 0.82
Active cancer 60 (24) 46 (21) 14 (45) 0.004
# of Comorbidities
0.31
None 17 (7) 16 (8) 1 (3)
1 34 (14) 31 (15) 2 (7)
≥2 198 (79) 160 (77) 26 (90)
Tobacco use
0.10
Never 130 (52) 118 (58) 12 (43)
Prior 60 (24) 48 (24) 12 (43)
Current 42 (17) 38 (19) 4 (14)
Enrollment location
0.12ICU 120 (48) 101 (46) 19 (61)
Floor 129 (52) 117 (54) 12 (39)
Renal Function
Baseline SCr, mg/dl 1.2 ± 0.5 1.2 ± 0.5 1.2 ± 0.5 0.44
Baseline GFR3 68.5 ± 30 68 ± 30 72 ± 28 0.49
Stage of AKI at enrollment
0.001Stage 1 207 (83) 188 (86) 19 (61)
Stage 2 42 (17) 30 (14) 12 (39)
Stage of AKI at peak SCr
0.006
Stage 1 176 (71) 162 (74) 14 (45)
Stage 2 41 (16) 33 (15) 8 (26)
Stage 3 18 (7) 13 (6) 5 (16)
Stage 3-Dialysis4 14 (6) 10 (5) 4 (13)
AKI type
ATN 51 (20) 40 (18) 11 (35) 0.03
Table 1 Baseline characteristics and outcomes by urine
YKL-40 value (Continued)
Pre-renal 164 (66) 151 (69) 13 (42) 0.003
Other 34 (14) 27 (12) 7 (23) 0.12
Discharge SCr, mg/dL 1.4 ± 0.7 1.4 ± 0.7 1.3 ± 0.5 0.34
Values are n (%) or mean ± SD. AKI, acute kidney injury; ATN, acute tubular
necrosis; CKD, chronic kidney disease (if specifically listed in patient medical
history); ACEi/ARB, angiotensin-converting enzyme inhibitor or angiotensin II
receptor blocker medications; CHF, congestive heart failure; CAD, coronary
artery disease; ICU, intensive care unit; SCr, serum creatinine.
1Data for the presence/absence of the characteristics listed were missing in no
more than 5 patients each except for baseline proteinuria (missing for 51
patients) and ACEi/ARB use (missing for 7 patients). The values or percentages
shown for each characteristics account for non-missing data only.
2Chi-squared or t-test. Values in boldface are significant at P<0.05.
3GFR (in ml/min per 1.73 m2) was estimated by the 4-variable Modification of
Diet in Renal Disease equation.
4Those acutely dialyzed for AKI; excludes those with stage 3 AKI who were
not dialyzed.
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gender, non-White race, baseline GFR, diabetes, hyper-
tension and surgery before AKI. We used a predefined
cutoff of ≥5 ng/ml for all analyses based on the median
urine YKL-40 value for recipients with immediate graft
function in previously published results from our kidney
transplant cohort [13]. We used multivariate logistic re-
gression, incorporating variables in the baseline clinical
model, to calculate odds ratios (95% confidence interval)
for the primary outcome according to YKL-40 value. We
also determined the continuous net reclassification index
(cNRI) and integrated discrimination index (IDI) as sug-
gested by Pencina and colleagues [19,20].
We performed secondary analyses combining urine
YKL-40 with our previously reported results for urine
NGAL after determining the Pearson correlation coeffi-
cient for these biomarkers. We first divided the cohort
by the upper quartile NGAL value (i.e., above 235 ng/ml),
representing the most severely injured group according
to this biomarker, and then subdivided the upper
NGAL quartile by YKL-40 above or below 5 ng/ml.
We compared primary outcome rates in the three non-
overlapping groups using chi-squared tests. We also evalu-
ated the distribution of adjudicated AKI type according
to this biomarker pattern. Based on our preclinical under-
standing that YKL-40 is released in the setting of severe
injury [13], we performed this simple step-wise approach
for combining biomarkers to explore the potential for
added information with YKL-40. We subsequently com-
pared median (interquartile range) urine levels for both
YKL-40 and NGAL based on the presence or absence of
key baseline clinical characteristics using Mann–Whitney
U tests. All analyses were performed with SAS version 9.3
for Windows (SAS Institute, Cary, NC). A Type I error
of 0.05 (two-tailed) was considered statistically significant
for all analyses.
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Cohort description and YKL-40 measurements
A total of 284 hospitalized patients with AKI were en-
rolled in the study, and after exclusions (see previous
description), 249 were available for analysis. Seventy-two
patients (29%) developed the primary outcome (progres-
sion of AKI stage or in-hospital death). Baseline charac-
teristics are summarized in Table 1. Median urine levels
for both YKL-40 and NGAL separated by these baseline
characteristics are provided in Table 2.
The median (10th-90th percentile) value for urine YKL-40
was 0.2 (0.02-13) ng/ml. Our prior study demonstratedTable 2 Urine YKL-40 and NGAL values by baseline character
Clinical characteristics YKL-40, ng/ml
N Median (IQR)
Pre-existing CKD
No 182 0.26 (0.08-0.85)
Yes 62 0.08 (0.03-0.31)
Pre-existing proteinuria
No 135 0.25 (0.07-0.59)
Yes 63 0.27 (0.07-2.33)
ACEi/ARB at enrollment
No 154 0.25 (0.08-1.05)
Yes 88 0.10 (0.06-0.54)
Hypertension
No 77 0.21 (0.08-0.68)
Yes 171 0.18 (0.06-0.97)
Diabetes
No 145 0.18 (0.05-0.66)
Yes 102 0.22 (0.07-1.41)
CHF
No 154 0.27 (0.07-1.41)
Yes 92 0.13 (0.05-0.54)
CAD
No 145 0.25 (0.07-0.93)
Yes 102 0.17 (0.06-0.71)
Stroke
No 213 0.18 (0.06-0.81)
Yes 34 0.24 (0.06-2.63)
Liver failure/Cirrhosis
No 222 0.18 (0.06-0.82)
Yes 27 0.30 (0.10-1.05)
Active cancer
No 188 0.17 (0.06-0.63)
Yes 60 0.29 (0.06-2.48)
IQR, interquartile range; CKD, chronic kidney disease (if specifically listed in patient me
receptor blocker medications; CHF, congestive heart failure; CAD, coronary artery disea
1Mann–Whitney U test. Values in boldface are significant at P<0.05.that recipients with the most rapid improvement in renal
function immediately after kidney transplant had median
urinary YKL-40 levels of 5 (0–60.7) ng/ml [13]. Eighty-
eight percent of the current cohort had urinary levels
below 5 ng/ml (Figure 1), and of those, 69% were adjudi-
cated as pre-renal. In contrast, only 42% of those with
YKL-40 ≥ 5 ng/ml were classified as pre-renal (P = 0.003).
Of the 31 patients with YKL-40 ≥ 5 ng/ml, 16 (52%) had
the primary outcome compared to 56/218 (26%) of those
with YKL-40 < 5 ng/ml (P = 0.003). For the individual com-
ponents of the primary outcome, 12/31 (39%) versus
34/218 (16%) had progression of AKI stage (P = 0.002),istics
NGAL, ng/ml
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Figure 1 Distribution of urine YKL-40. YKL-40≥ 5 ng/ml was set
at 5 ng/ml for this histogram. The 10th, 50th and 90th percentile
values were 0.02, 0.2 and 13 ng/ml, respectively.
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(P = 0.03), respectively.
In regression analyses, the unadjusted odds ratio for the
primary outcome with YKL-40 ≥ 5 ng/ml was 3.1 (1.4-6.6),
and after adjusting for the variables in the clinical model,
the odds ratio increased slightly to 3.4 (1.5-7.7). Our pre-
defined cutoff for YKL-40 also significantly improved risk
reclassification, particularly for patients that did not de-
velop the outcome (Figure 2). Adding YKL-40 ≥ 5 ng/ml to
the clinical model resulted in a cNRI of 29% (2.0%-56%,
p = 0.04) and an IDI of 2% (0.04%-4.0%, P = 0.03).
Injury-repair biomarker combination
There was statistically significant, though fairly modest
correlation between NGAL and YKL-40 in this cohort
(r = 0.47, P < 0.001). The step-wise combination of NGAL
and YKL-40 produced a straightforward algorithm for de-
termining outcome risk (Figure 3A). The first group, with
NGAL values below the fourth quartile, had the lowest risk
of developing the outcome at 20%. The outcome rate in
the first group was significantly different from the
rates in both the second and the third groups—NGAL
in the fourth quartile subdivided by YKL-40 less than
or ≥5 ng/ml, respectively (P < 0.001 for both comparisons).
The outcome rates were also statistically different between
the second and third groups at 45% and 71%, respectively
(P = 0.05). The same three-group injury-repair biomarker
pattern also corresponded with AKI type with an in-
creasing proportion of patients adjudicated as ATN and a
decreasing proportion adjudicated as pre-renal (overall
chi-square P < 0.001, Figure 3B). Of note, only 10 patients
in the first group, with NGAL values below the fourth
quartile, also had YKL-40 values ≥5 ng/ml, and only one of
these patients developed the primary outcome (in-hospital
death, no progression in AKI stage).Discussion
This is the first investigation of YKL-40 in urine from
injured native human kidneys. Our findings support the
hypothesis that urine YKL-40, a “repair-phase” protein,
may have utility as a marker of severe kidney injury. The
current cohort was more heterogeneous and likely had
lower overall structural AKI severity than the cohort of
deceased-donor kidney transplants we previously evalu-
ated [13]. In keeping with this, we found urine YKL-40
in hospitalized patients with AKI of any cause to be de-
tectable, but with levels that were markedly lower than
those seen in peri-operative kidney transplant recipients.
Our analyses also show the potential clinical benefit of
considering a biomarker cutoff based on prior experi-
ence in complementary settings. We found a modest
association between high levels of YKL-40 and AKI pro-
gression or death—patients with YKL-40 ≥ 5 ng/ml had a
three-fold increase in the odds of this outcome.
In addition, adding YKL-40 ≥ 5 ng/ml to our baseline
clinical model significantly improved risk reclassification
primarily for patients who would not develop the primary
outcome. This improvement is clearly seen in Figure 2B,
where overwhelmingly more patients without the outcome
were correctly reclassified as lower predicted risk rather
than higher predicted risk after adding YKL-40 to the clin-
ical model. Furthermore, when combined in a simple
step-wise approach with NGAL, the best injury biomarker
previously measured in this cohort, YKL-40 ≥ 5 ng/ml sig-
nificantly partitioned the high-risk group (defined by an
NGAL value in the upper quartile) into moderate-risk and
very high-risk groups. Taken together, these findings illus-
trate the concept that incorporating an additional bio-
marker, which has complementary mechanisms of action,
can enhance the utility of other biomarkers or even im-
prove upon clinical prediction models.
BRP-39/YKL-40 is a 39 kDa protein that lacks true
chitinolytic activity, like all chitinase-like proteins, and is
produced by several cell types including epithelial cells
in the airway and colon, chondrocytes, hepatic stellate
cells, vascular smooth muscle cells, fibroblasts and differ-
entiated macrophages [21]. Our group recently provided
preclinical and translational data regarding BRP-39/
YKL-40 expression in the kidney, detectable urine levels,
and the physiologic role it plays in limiting tubular cell
apoptosis during the repair phase of AKI [13]. This
work is an example of ongoing efforts to develop effect-
ive biomarker panels to assess renal health and progno-
sis in different clinical settings. As a proof of concept,
the current study suggests that YKL-40 can be non-
invasively measured in urine at the first clinical sign of
AKI in general hospitalized patients (e.g., a rise in SCr
or drop in urine output) and the results used in combin-
ation with other biomarkers (e.g., NGAL levels to quan-
titate distal nephron damage) in order to assess renal
,Reclassified lower risk  N=53
Reclassified higher risk, N=19
Reclassified lower risk, N=155
Reclassified higher risk, N=22
A Patients with the outcome
B P ti nt  with
Risk of Clinical Model Onl
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Figure 2 Predicted risk using the clinical model plus urine YKL-40 versus the clinical model alone. Each patient has a predicted risk for
the outcome determined by their individual factors in the clinical (regression) model. Adding YKL-40 to the model results in a new predicted risk
for each patient based on their YKL-40 value (above or below 5 ng/ml). For each patient, the predicted risk from the clinical model alone is plotted
(horizontal axis) against the new predicted risk (vertical axis) after adding YKL-40 to the model. The dotted line represents no change in predicted
risk (unity) after adding YKL-40. Changes in predicted risk can be considered appropriate or inappropriate based on the true outcome status. For
example, in patients that ultimately developed the outcome (A), increasing predicted risk would be appropriate and decreasing predicted risk
would be inappropriate. The opposite is true for patients that did not develop the outcome (B)–decreasing predicted risk would be appropriate
and increasing predicted risk would be inappropriate. Darker symbols here indicate patients that were reclassified in the appropriate direction.
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http://www.biomedcentral.com/1471-2369/15/133injury-repair processes in real-time and potentially im-
prove outcome prediction.
While much AKI biomarker research has appropriately
focused on diagnosing AKI earlier than SCr [22-25],
there have been fewer advances in identifying novel bio-
markers that can effectively classify patients with AKI asmore likely versus less likely to progress [26,27]. A key
application for a tool of this kind may lie in excluding
patients at low risk of progression from enrollment into
trials that evaluate management strategies initiated imme-
diately after the diagnosis of AKI. Clinicians frequently
use the term “pre-renal” AKI to describe these low-risk
29%
%45%02
Outcome Risk in the Entire Cohort
72 / 249
4Q ni LAGN4Q < LAGN
















































NGAL in Q4 &
YKL-40 < 5 ng/ml
(n=42)
NGAL in Q4 &
YKL-40 ≥ 5 ng/ml
(n=21)
B
Figure 3 Cohort partitioning by urine biomarkers with outcome risk and adjudicated acute kidney injury type. (A) The cohort was
partitioned into those with urine neutrophil gelatinase-associated lipocalin (NGAL) values in the fourth quartile (Q4, ≥235 ng/ml) and those in the
first three quartiles. The former group was then separated into those with urine YKL-40≥ 5 ng/ml and <5 ng/ml, respectively. The percentage of
patients within each group/node that experienced the primary outcome is shown, with horizontal bar widths that are proportional to the numbers of
patients in that node. (B) The percentage of patients within each terminal node that developed the primary outcome is depicted here as a (dotted) line
graph, and the distribution of adjudicated acute kidney injury type within each terminal node is depicted as a stacked bar graph with corresponding
percentages as shown. ATN, acute tubular necrosis.
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in retrospect after observing the patient’s response to a
fluid challenge. Our current findings suggest that a
straightforward combination of kidney injury-repair bio-
markers may be useful for prospectively risk-stratifying po-
tential trial subjects. To most effectively assess different
treatment strategies in the context of a controlled trial,
only participants with significant structural renal injuryand at high risk for progression (e.g., high NGAL and
high YKL-40 values) should potentially be randomized. As
an aside but of particular interest to the AKI field, the mis-
classification of “pre-renal” patients as having structural
AKI may also be diluting or otherwise complicating studies
of novel biomarkers to diagnose AKI earlier than SCr [28].
There are some limitations to consider. First, this was
an ancillary study to a prospectively collected observational
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press purpose of evaluating the performance of traditional
and novel biomarkers, like YKL-40, as they relate to in-
hospital outcomes (i.e., to perform appropriate phase 3 bio-
marker development studies) [14]. In addition, we followed
proper biorepository procedures including validated and
blinded biomarker measurements from sample aliquots
that had not undergone prior freeze-thaw cycles. The use
of a dichotomous cutoff value for a continuous measure-
ment can be considered a limitation; however, the value of
5 ng/ml for YKL-40 was pre-specified based on our previ-
ous findings in a separate patient cohort. In addition, sam-
ple size limited our ability to evaluate multiple biomarker
combinations and comparisons. We therefore controlled
for the same confounders and evaluated a simple, repre-
sentative combination of YKL-40 with the best injury bio-
marker based on our prior analyses. Lastly, this study was
limited by a lack of post-hospitalization information and
outcomes given IRB approval with waiver of consent to
study the effects of AKI on inpatient outcomes only.Conclusions
In summary, YKL-40 is a repair-phase protein that is de-
tectable in urine on the first day of clinically apparent
AKI and provides only modest prognostic potential on
its own. Our findings suggest that there may be utility in
combining YKL-40 with other biomarkers like NGAL to
refine AKI prognosis and better determine the relationship
between injury severity and the degree of repair activation.
Further studies are needed to validate the performance of
YKL-40 in a large population of patients with AKI and, in
particular, to follow trends in this marker of renal injury
and repair over the course of disease progression and/or
recovery. The kidney is clearly an intricate organ with sev-
eral cell types that are responsible for multiple homeostatic
functions. As we continue to learn more about the com-
plex mechanisms that maintain and repair the renal-
urinary system following periods of stress and injury, we
envision developing better clinical AKI biomarker panels
that provide useful diagnostic and prognostic information
relative to those mechanisms. With further insights into
the renal responses to acute injury, novel biomarkers like
YKL-40 may also begin to give us better information about
overall kidney health and could suggest new therapeutic
targets for study in humans.Abbreviations
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